Christobel Selecky insider trades: ImmunityBio (IBRX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Christobel reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | IBRX | ↓ Sell | 159,478 | $9.02 | $1.4M | Direct | Jul 6, 2026 (5d) |
| Jun 30, 2026 | IBRX | ↓ Sell | 96,722 | $9.01 | $871K | Direct | Jul 1, 2026 (1d) |
| Feb 23, 2026 | IBRX | ↓ Sell | 25,000 | $10.00 | $250K | Direct | Feb 24, 2026 (1d) |
| Jan 20, 2026 | IBRX | ↓ Sell | 75,000 | $5.84 | $438K | Direct | Jan 21, 2026 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other IBRX insiders
Open-market trades in the last 12 months
About Christobel Selecky's insider trades
Christobel Selecky is a director at ImmunityBio (IBRX). Since Jan 20, 2026, Christobel has reported no open-market purchases and 4 sales worth $3.0M on SEC Form 4. In the last 12 months: 4 sales ($3.0M).
Their filings also include grants and awards (7 filings), option exercises (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IBRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.